Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Interview with CEO on Upcoming Clinical Trial

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon Mar 28, 2023 3:58pm

125 Views

Post# 35365369

Interview with CEO on Upcoming Clinical Trial

A US survey found that 5% of people (approximately 12.2 million adults) reported experiencing chronic cough in the previous 12 months. The chronic cough market is expected to reach $11.38B by 2029.

I’ve been following AGN.c AGNPF (a clinical stage drug development company). This interview with their CEO gives updates on the previously announced 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough that will begin in Q3.

There’s clearly a huge opportunity in finding a solution to chronic cough and AGN is poised to find the solution.

https://www.youtube.com/watch?v=zpvV0-fELgc

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec